Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1755-1762

  Banno, Kouji ^a   Kisu, Iori ^a   Yanokura, Megumi ^a   Tsuji, Kosuke ^a   Masuda, Kenta ^a   Ueki, Arisa ^a   Kobayashi, Yusuke ^a   Yamagami, Wataru ^a   Nomura, Hiroyuki ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Dienogest; Endometrial cancer; Medroxyprogesterone acetate; Progesterone receptor; Progestin

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 AZA 2' DEOXYCYTIDINE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; DANAZOL; DIENOGEST; EPIDERMAL GROWTH FACTOR RECEPTOR; GESTAGEN; GONADORELIN AGONIST; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROSTAGLANDIN E2; PROTEIN P27;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BLEEDING; BREAST DISEASE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; GENITAL BLEEDING; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; IN VITRO STUDY; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; POSTOPERATIVE CARE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NANDROLONE; PROGESTINS;

EID: 84861777930     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1384     Document Type: Review

References (52)

1. Vercellini P, Cortesi I and Crosignani PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 68: 393-401, 1997. (Pubitemid 27412901)
2. Moghissi KS and Boyce CR: Management of endometriosis with oral medroxyprogesterone acetate. Obstet Gynecol 47: 265-267, 1976.
3. Schlaff WD, Dugoff L, Damewood MD and Rock JA: Megestrol acetate for treatment of endometriosis. Obstet Gynecol 75: 646-648, 1990. (Pubitemid 20110184)
4. Fedele L, Bianchi S, Zanconato G, Portuese A and Raffaelli R: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 75: 485-488, 2001. (Pubitemid 32175660)
5. Sacco K, Portelli M, Pollacco J, Schembri-Wismayer P and Calleja-Agius J: The role of prostaglandin E2 in endometriosis. Gynecol Endocrinol 27: 1-5, 2011.
6. Okada H, Nakajima T, Yoshimura T, Yasuda K and Kanzaki H: The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod 7: 341-347, 2001. (Pubitemid 32288323)
7. Fu L, Osuga Y, Morimoto C, Hirata T, Hirota Y, Yano T and Taketani Y: Dienogest inhibits BrdU uptake with G(0)/G(1) arrest in cultured endometriotic stromal cells. Fertil Steril 89: 1344-1347, 2008. (Pubitemid 351680084)
8. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T and Terakawa N: Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 83: 1530-1535, 2005. (Pubitemid 40615830)
9. Haney AF and Weinverg JB: Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate. Am J Obstet Gynecol 159: 450-454, 1988.
10. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H and Terakawa N: Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis - a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91: 675-681, 2009.
11. Harada T and Taniguchi F: Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond Engl) 6: 27-35, 2010.
12. Shimizu Y, Takeuchi T, Mita S, et al: Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 15: 693-701, 2009.
13. Ito K, Utsunomiya H, Yaegashi N and Sasano H: Biological roles of estrogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocr J 54: 667-679, 2007. (Pubitemid 351377743)
14. Utsunomiya H, Suzuki T, Ito K, et al: The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endocrinol 58: 696-703, 2003. (Pubitemid 36702728)
15. Yang S, Fang Z, Gurates B, Tamaura M, Miller J, Ferrer K and Bulun SE: Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol Endocrinol 15: 2093-2105, 2001. (Pubitemid 33141129)
16. Urbański K, Karolewski K, Kojs Z, Klimek M and Dyba T: Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 15: 98-104, 1993. (Pubitemid 24052682)
17. McDonald CC, Thorogood J and Mason MK: A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynecol 95: 166-174, 1988.
18. Vergote I, Kjorstad K, Abeler V and Kolstad P: A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64: 1011-1016, 1989. (Pubitemid 19208849)
19. De Palo G, Mangioni C, Periti P, Del Vecchio M and Marubini E: Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 29A: 1133-1140, 1993. (Pubitemid 23156638)
20. Martin-Hirsch PL, Lilford RJ and Jarvis GJ: Adjuvant progestagen therapy for the treatment of endometrial cancer: review and metaanalyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 65: 201-207, 1996. (Pubitemid 26103207)
21. Thigpen JT, Blessing JA and DiSaia PJ: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12: 1408-1414, 1994. (Pubitemid 24206239)
22. Thigpen JT, Brady MF and Alvarez RD: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736-1744, 1999. (Pubitemid 29269242)
23. Rose PG, Brunetto VL, van Le L, Bell J, Walker JL and Lee RB: A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78: 212-216, 2000. (Pubitemid 30650356)
24. Ashino-Fuse, H, Takano Y, Oikawa T, Shimamura M and Iwaguchi T: Medroxyprogesterone acetate, an anti-cancer and antiangiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44: 859-864, 1989. (Pubitemid 20007984)
25. Randall TC and Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated arcinoma of the endometrim in woman under 40. Obstet Gynecol 90: 434-440, 1997. (Pubitemid 27357938)
26. Kim YB, Holscneider CH, Ghosh K, Nieberg RK and Montz FJ: Progetin alone as primary treatment of endometrial carcinoma in premenopausal woman. Report of seven cases and review of the literature. Cancer 79: 320-327, 1997. (Pubitemid 27029896)
27. Kaku T, Yoshikawa H, Tsuda H, et al: Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 167: 39-48, 2001. (Pubitemid 32373267)
28. Imai M, Jobo T, Sato R, Kawaguchi M and Kuramoto H: Medroxyprogesterone acetate for patients with adenocarcinoma of the endometrium who wish to presrve the uteus-usefulness and limitations. Eur J Gynaecol Oncol 22: 217-220, 2001. (Pubitemid 32757874)
29. Niwa K, Tagami K, Lian Z, Onogi K, Mori H and Tamaya T: Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 112: 317-320, 2005. (Pubitemid 40314007)
30. Yahata T, Fujita K, Aoki Y and Tanaka K: Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21: 1070-1075, 2005.
31. Ushijima K, Yahata H, Yoshikawa H, et al: Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25: 2798-2803, 2007. (Pubitemid 47123189)
32. Yamazawa K, Hirai M, Fujito A, et al: Fertility-preserving treatment with progestin, and pathological criteria to predict response,in young women with endometrial cancer. Hum Reprod 22: 1953-1958, 2007. (Pubitemid 47062765)
33. Minaguchi T, Nakagawa S, Takazawa Y, et al: Combined phospho- Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 248: 112-122, 2006.
34. Kamoi S, Ohaki Y, Mori O, Kurose K, Fukunaga M and Takeshita T: Serial histologic observation of endometrial adenocarcinoma treated wuth high-dose progestin until complete disappearance of carcinomatous foci-review of more than 25 biopsies from five patients. Int J Gynecol Cancer 18: 1305-1314, 2008.
35. Jobo T, Kawaguchi M, Imai M and Kuramoto H: Treatment for complex atypical hyperplasia of the endometrium. Eur J Gynaecol Oncol 22: 365-368, 2001. (Pubitemid 33144546)
36. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R and Kurman RJ: Intrauterine progesterone treatment of early endometrial cancer. Am J Obctet Gynecol 186: 651-657, 2002. (Pubitemid 34494341)
37. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC and Levenback C: Hormonal therapy for the management of grade 1 endometrial adenocarcinoma. Gynecol Oncol 95: 133-138, 2004. (Pubitemid 39286288)
38. Yang S, Thiel KW, De Geest K and Leslie KK: Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 12: 205-212, 2011.
39. Ren Y, Liu X, Ma D, Feng Y and Zhong N: Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet 175: 107-116, 2007. (Pubitemid 46855929)
40. Xiong Y, Dowdy SC, Podratz KC, Jin F, Attewell JR, Eberhardt NL and Jiang SW: Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 65: 2684-2689, 2005. (Pubitemid 40490068)
41. Kondo Y: Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 50: 455-463, 2009.
42. Balch C, Matei DE, Huang TH-M and Nephew KP: Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2: 419-447, 2010.
43. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S and Dahiya R: Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res 61: 97-102, 2001. (Pubitemid 32095706)
44. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC and Jiang S-W: Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 99: 135-141, 2005. (Pubitemid 41354594)
45. Ai Z, Wang J, Wang Y, Lu L, Tong J and Teng Y: Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. Cancer 116: 3603-3613, 2010.
46. Katsuki Y, Shibutani Y, Aoki D and Nozawa S: Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 79: 169-176, 1997. (Pubitemid 26425523)
47. Nakamura M, Katsuki Y, Shibutani Y and Oikawa T: Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cellinduced angiogenesis. Eur J Pharmacol 386: 33-40, 1999. (Pubitemid 30009620)
48. Katayama H, Katayama T, Uematsu K, et al: Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod 25: 2851-2858, 2010.
49. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K and Kyo S: Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 76: 60-67, 2011.
50. The Centers for Diseases Control Cancer and Steroid Hormone Study: Oral contraceptive use and the risk of endometrial cancer. JAMA 249: 1600-1604, 1983.
51. Vessey MP and Painter R: Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br J Cancer 71: 1340-1342, 1995.
52. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ and Gupta JK: The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia - a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 139: 169-175, 2008.